Oncotarget

Research Papers:

CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells

Christian B. Schiller, Todd A. Braciak, Nadja C. Fenn, Ursula J. E. Seidel, Claudia C. Roskopf _, Sarah Wildenhain, Annemarie Honegger, Ingo A. Schubert, Alexandra Schele, Kerstin Lämmermann, Georg H. Fey, Uwe Jacob, Peter Lang, Karl-Peter Hopfner and Fuat S. Oduncu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:83392-83408. https://doi.org/10.18632/oncotarget.13110

Metrics: PDF 844 views  |   HTML 1429 views  |   ?  


Abstract

Christian B. Schiller1,*, Todd A. Braciak2,*, Nadja C. Fenn1,*, Ursula J. E. Seidel3,*, Claudia C. Roskopf2,*, Sarah Wildenhain1,*, Annemarie Honegger*, Ingo A. Schubert5, Alexandra Schele1, Kerstin Lämmermann2, Georg H. Fey6, Uwe Jacob6, Peter Lang3, Karl-Peter Hopfner1,#, Fuat S. Oduncu2,#

1Department of Biochemistry and Gene Center, Ludwig-Maximilians-University, Munich, Germany

2Division of Hematology and Oncology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany

3Department of General Paediatrics, Oncology/Haematology, University Children’s Hospital Tübingen, Tübingen, Germany

4Department of Biochemistry, University of Zurich, Zurich, Switzerland

5Department of Biology, University of Erlangen-Nuremberg, Erlangen, Germany

6Westend-Innovation, Munich, Germany

*CBS, TAB, NCF, UJES, CCR and SW are co-first authors in this study

#KPH and FSO are co-senior authors in this study

Correspondence to:

Claudia C. Roskopf, email: Claudia.Roskopf@med.uni-muenchen.de

Keywords: single chain triplebody, antibody-dependent cellular cytotoxicity, gamma delta T cell, leukemia, immunotherapy

Received: June 30, 2016    Accepted: October 03, 2016    Published: November 04, 2016

ABSTRACT

Triplebodies are antibody-derived recombinant proteins carrying 3 antigen-binding domains in a single polypeptide chain. Triplebody SPM-1 was designed for lysis of CD19-bearing malignant B-lymphoid cells through the engagement of CD16-expressing cytolytic effectors, including NK and γδ T cells.

SPM-1 is an optimized version of triplebody ds(19-16-19) and includes humanization, disulfide stabilization and the removal of potentially immunogenic sequences. A three-step chromatographic procedure yielded 1.7 - 5.5 mg of purified, monomeric protein per liter of culture medium. In cytolysis assays with NK cell effectors, SPM-1 mediated potent lysis of cancer-derived B cell lines and primary cells from patients with various B-lymphoid malignancies, which surpassed the ADCC activity of the therapeutic antibody Rituximab. EC50-values ranged from 3 to 86 pM. Finally, in an impedance-based assay, SPM-1 mediated a particularly rapid lysis of CD19-bearing target cells by engaging and activating both primary and expanded human γδ T cells from healthy donors as effectors.

These data establish SPM-1 as a useful tool for a kinetic analysis of the cytolytic reactions mediated by γδ T and NK cells and as an agent deserving further development towards clinical use for the treatment of B-lymphoid malignancies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13110